Keywords: alltracel, six-month, ebitda, climbs, irish, drugmaker, pharmaceuticals
Alltracel's six-month EBITDA climbs 64%
Article | 24 September 2007
Irish drugmaker Alltracel Pharmaceuticals says that, for the six months ended June 30, 2007, its earnings before interest, taxes, depreciation and amortization ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
